Skip to main content

Michael J. McElhaugh

Equibles does not estimate personal net worth.

Get an email with a short summary when Arbutus Biopharma Corp publishes a filing, an earnings call transcript or a press release.

Get ABUS alerts

About Michael J. McElhaugh

Michael J. McElhaugh is recorded as COO at Arbutus Biopharma Corp (ABUS). The newest filing on record that lists Michael J. McElhaugh as COO at Arbutus Biopharma Corp (ABUS) is dated April 12, 2023. Arbutus Biopharma Corp reported in an 8-K filed February 25, 2025 that Michael J. McElhaugh resigned as Interim President and Chief Executive Officer, effective February 24, 2025. The same filing states: “None of the departures from the Board described herein are the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.” Arbutus Biopharma Corp reported in an 8-K filed February 25, 2025 that Michael J. McElhaugh resigned as member of the Board of Directors, effective February 24, 2025. The same filing states: “None of the departures from the Board described herein are the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.” Arbutus Biopharma Corp reported in an 8-K filed January 4, 2024 that Michael J. McElhaugh was appointed Interim President and Chief Executive Officer, effective January 1, 2024. Equibles holds 5 filed executive changes naming Michael J. McElhaugh; each is listed under recent activity with its source filing. The proxy statement of Arbutus Biopharma Corp reports total compensation of $3,578,150 for Michael J. McElhaugh in fiscal 2025, including a base salary of $109,658. Disclosed compensation is on record for 6 fiscal years. Michael J. McElhaugh has spoken on 1 earnings call across 1 company, most recently for Arbutus Biopharma Corp on August 1, 2024. Arbutus Biopharma Corp is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Arbutus Biopharma Corp includes Lindsay Androski (CEO, Chairman and Board Member), Mark J. Murray (CEO), Tuan Nguyen (CFO) and 7 others.

“Ms. Androski succeeds Michael J. McElhaugh, who ceased serving as the Company's Interim President and Chief Executive Officer concurrent with Ms. Androski's appointment as President and Chief Executive Officer.”
“None of the departures from the Board described herein are the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Arbutus Biopharma Corp Form 8-K, filed February 25, 2025 · Read the filing
“On February 24, 2025, all of the members of the Board of Directors (the "Board") of Arbutus Biopharma Corporation (the "Company") resigned from the Board and all committees thereof, effective immediately: ... (ii) Michael J. McElhaugh;”
“None of the departures from the Board described herein are the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Arbutus Biopharma Corp Form 8-K, filed February 25, 2025 · Read the filing

Michael J. McElhaugh on recent calls

“In the second quarter of 2024, we made significant advancements in our pursuit of developing a functional cure for patients with hepatitis B and driving value for our company and shareholders.”
CEO, Arbutus Biopharma Corp Q2 FY2024 Earnings Call ·

Affiliation history

Company network

Leadership on record at Arbutus Biopharma Corp

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Arbutus Biopharma Corp (ABUS) $109,658 $3,578,150
2024 Arbutus Biopharma Corp (ABUS) $642,500 $2,110,083
2023 Arbutus Biopharma Corp (ABUS) $483,000 $1,620,485
2022 Arbutus Biopharma Corp (ABUS) $448,750 $1,315,235
2021 Arbutus Biopharma Corp (ABUS) — —
2020 Arbutus Biopharma Corp (ABUS) $415,000 $1,087,791

Recent activity